Working… Menu

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00346684
Recruitment Status : Completed
First Posted : June 30, 2006
Last Update Posted : August 12, 2008
Information provided by:
University of Cologne

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 2007
Study Completion Date : No date given